* Harvard Bioscience Inc HBIO.OQ HBIO.O is expected to show
a rise in quarterly revenue when it reports results on August
5.
* The Holliston, Massachusetts-based company is expected to
report a 18.7% increase in revenue to $27.668 million from
$23.31 million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Harvard Bioscience Inc
is for earnings of 6 cents per share. For the same quarter last
year, the company reported earnings of 5 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Harvard
Bioscience Inc is $10, about 20.1% above its last closing
price of $7.99.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 0.03 0.03 0.05 Beat 50
Dec. 31 2020 0.07 0.08 Beat 23.1
Sep. 30 2020 0.03 0.04 0.04 Met 14.3
Jun. 30 2020 -0.01 -0.01 0.05 Beat 600
Mar. 0.03 0.03 -0.01 Missed -130
31 2020
Dec. 31 2019 0.09 0.09 0.08 Missed -7.7
Sep. 30 2019 0.06 0.05 0.04 Missed -25
Jun. 30 2019 0.04 0.04 0.04 Met 0
This summary was machine generated August 3 at 14:57 GMT. All
figures in US dollars unless otherwise stated